	Application No.	Applicant(s)
Notice of Allowability	10/608,783	NIGAM ET AL.
	Examiner	Art Unit
	Allison M. Ford	1651
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1. ☑ This communication is responsive to telephonic interview of 8 August 2007 with Michael Reed (Applicant's Rep). 2. ☑ The allowed claim(s) is/are 1.4-7 and 68. 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 2. ☐ Certified copies of the priority documents have been received in Application No 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	Notice of Informal F	atent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	(PTO-413),
3. Information Disclosure Statements (PTO/SB/08),	Paper No./Mail Da 7. ⊠ Examiner's Amendr	ment/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ☐ Examiner's Stateme	ent of Reasons for Allowance

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be

unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure

consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Michael

Reed on 8 August 2007.

The application has been amended as follows:

Please re-write claim 1 as follows:

-- Claim 1. A method of propagating ureteric bud cells in culture, the method comprising:

a) culturing ureteric bud cells on a biocompatible matrix in a pleiotrophin-supplemented medium,

wherein the medium has not previously been conditioned with cells from metanephric mesenchyme, to

induce the ureteric bud cells to undergo branching morphogenesis to generate a population of ureteric bud

cells with tubular branches; and

b) subculturing said ureteric bud cells with tubular branches on a biocompatible matrix in a

pleiotrophin-supplemented medium, wherein the medium has not previously been conditioned with cells

from metanephric mesenchyme.

Please re-write claim 5 as follows:

-- Claim 5. The method of claim 1, wherein the medium comprises fibroblast growth factor-1 (FGF1), or

a functional equivalent thereof .--

Please add new claim 68 as follows:

Application/Control Number: 10/608,783

Art Unit: 1651

-- Claim 68. The method of claim 1, wherein the medium comprises a glial cell line derived neurotrophic

Page 3

factor (GDNF), or functional equivalent thereof, and fibroblast growth factor-1 (FGF1), or a functional

equivalent thereof. --

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Allison M. Ford whose telephone number is 571-272-2936. The examiner can normally be

reached on 7:30-5 M-Th, alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where

this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained

from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer

Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR

CANADA) or 571-272-1000.

Leon B Lankford, Jr

-Art Unit 1651

Art Unit 1691